Strados Labs is a digital health company focused on helping clinicians and patients take control of chronic lung diseases. Strados Labs' RESP Biosensor is a FDA-cleared, first-of-its-kind technology that allows clinicians and researchers to remotely monitor patients' respiratory status including coughing and wheezing from anywhere, anytime. Supported by machine learning, the RESP Biosensor has the potential to offer earlier insight into COPD and Asthma exacerbations across the patient journey, allowing for earlier interventions that can prevent hospitalizations. The RESP Biosensor is also used to demonstrate treatment efficacy in respiratory clinical trials, supporting patient self-reporting of symptoms with objective data in daily life. The company is based in Philadelphia and is privately owned.